SCHEMBL5580368

SCHEMBL5580368

COc1ccccc1CO[CH]c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.55
ABCB1 P08183 1/20 0.49
TAAR1 Q96RJ0 1/20 0.46
GRIN1 Q05586 2/20 0.46
GRIN2B Q13224 1/20 0.46
CHRM2 P08172 2/20 0.44
CHRM1 P11229 2/20 0.44
TRPA1 O75762 1/20 0.44
NFE2L2 Q16236 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2095156 0.79 IDO1 (0.60) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL14306607 0.78 IDO1 (0.58) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL65022 0.78 IDO1 (0.58) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL5778566 0.76 IDO1 (0.56) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL31290863 0.74 IDO1 (0.69) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL31048 0.74 IDO1 (0.69) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL10607688 0.74 IDO1 (0.69) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL26654 0.74 IDO1 (0.69) IDO1ABCB1TAAR1GRIN1CHRM2
SCHEMBL27844473 0.74 IDO1 (0.48) IDO1ABCB1TAAR1GRIN1GRIN2B
SCHEMBL4779293 0.72 ABCB1 (0.62) IDO1ABCB1TAAR1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7276511-B2 Benzylamine derivative ZERIA PHARMACEUTICAL CO., LTD. (JP) 2007-10-02 US disclosed
US-20060194841-A1 E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting ZERIA PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1650189-A1 BENZYLAMINE DERIVATIVE Zeria Pharmaceutical Co., Ltd. (JP) 2006-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194841-A1 E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting KCNAB1, BDKRB2, ARRB1 IDO1 587/4885ABCB1 845/4885TAAR1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.